Amber Salzman | Chief Executive Officer
Epicrispr Biotechnologies

Amber Salzman, Ph.D., is CEO of Epicrispr Biotechnologies, a biotechnology company developing epigenetic therapies. Dr. Salzman brings more than three decades of leadership experience in the pharmaceutical and biotechnology industries, including building and scaling multiple therapeutic platforms from early research through late-stage development.
Before joining Epicrispr, Dr. Salzman was President and CEO of Ohana Biosciences and President and CEO of Adverum Biotechnologies, a publicy-traded gene therapy company, which was acquired by Lilly.
She also served on the R&D executive team at GSK, and was responsible for global drug-development operations across multiple therapeutic areas. She oversaw clinical programs enrolling more than 30,000 patients worldwide, managed a team of 1,600 employees. She later served as CEO of Cardiokine, guiding the company through development and its eventual acquisition by Cornerstone Therapeutics.
Dr. Salzman currently serves on the boards of Osler Diagnostics (UK) and AviadoBio (UK). She holds a bachelor’s degree from Temple University and a Ph.D. in mathematics from Bryn Mawr College. Dr. Salzman also leads the Stop ALD Foundation, a nonprofit dedicated to advancing new treatments for adrenoleukodystrophy (ALD), inspired by her family’s experience with the disease.